Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5938 - Outcomes by prior transarterial chemoembolization (TACE) in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Clinical Research

Tumour Site

Hepatobiliary Cancers


Thomas Yau


Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282


T. Yau1, A. Cheng2, T. Meyer3, B. Ryoo4, J. Park5, H. Klümpen6, H.Y. Lim7, S. Kim8, J. Knox9, M. Patel10, A.B. El-Khoueiry11, R.K. Kelley12, G.K. Abou-Alfa13

Author affiliations

  • 1 Oncology, Queen Mary Hospital, 19428 - Hong Kong/CN
  • 2 -, National Taiwan University Hospital, Taipei/TW
  • 3 Medical Oncology, Royal Free Hospital, London/GB
  • 4 -, Asan Medical Center, University of Ulsan College of Medicine, 138-736 - Seoul/KR
  • 5 Center For Liver Cancer, National Cancer Center, Goyang-si/KR
  • 6 Department Of Medical Oncology, Academic Medical Center, Amsterdam/NL
  • 7 -, Samsung Medical Center, Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
  • 8 -, CHU Besançon, 25030 - Besançon/FR
  • 9 -, Princess Margaret Hospital, Toronto/CA
  • 10 -, Exelixis, Inc., South San Francisco/US
  • 11 Medical Oncology, USC/Norris Comprehensive Cancer Center, Los Angeles/US
  • 12 Division Of Hematology/oncology, Helen Diller Family Comprehensive Cancer Center, University of California, 94143 - San Francisco/US
  • 13 ., Memorial Sloan Kettering Cancer Center, New York/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5938


Pts with HCC and localized disease commonly receive treatment with TACE but often progress and require systemic therapy. In the CELESTIAL trial (NCT01908426), C, an inhibitor of MET, VEGFR, and AXL, improved overall survival (OS) and progression-free survival (PFS) vs P in previously treated pts with advanced HCC. Median OS was 10.2 mo for C vs 8.0 mo for P (HR 0.76, 95% CI 0.63–0.92; p = 0.0049), and median PFS was 5.2 mo for C vs 1.9 mo for P (HR 0.44, 95% CI 0.36–0.52; p < 0.0001) (Abou-Alfa, JCO 2018). Here, outcomes were analyzed for pts who received prior TACE.


707 pts were randomized 2:1 to receive C (60 mg qd) or P stratified by disease etiology, geographic region, and extent of disease. Eligible pts had pathologic diagnosis of HCC, Child-Pugh score A, and ECOG PS ≤ 1. Pts must have received prior sorafenib and could have received up to two lines of prior systemic therapy for HCC. Outcomes were analyzed by number of prior TACE treatments (0, ≥1, 1-2, ≥3).Table: 704P

No Prior TACEPrior TACE
C (N = 267)P (N = 126)C (N = 203)P (N = 111)C (N = 118)P (N = 52)C (N = 85)P (N = 59)
OS HR (95% CI)0.69 (0.54–0.90)0.82 (0.62–1.09)0.89 (0.59–1.37)0.80 (0.54–1.17)
PFS HR (95% CI)0.43 (0.33–0.54)0.50 (0.38–0.64)0.58 (0.41–0.84)0.38 (0.26–0.57)


Overall, 203 (43%) pts in the C arm and 111 (47%) pts in the P arm had received prior TACE with a median of 2 and 3 treatments, respectively. For pts who received TACE, 54% received 1-2 treatments and 46% received ≥3. 61% of pts enrolled in Asia, 39% in Europe, and 37% in North America received prior TACE. For pts who received prior TACE vs no TACE, 67% vs 76% received 1 prior systemic regimen and 32% vs 23% received 2. C was associated with improved OS and PFS vs P irrespective of prior TACE treatment (Table). Median OS was 11.4 mo for C vs 8.6 mo for P in pts with prior TACE and 9.5 mo for C vs 7.2 mo for P in pts with no prior TACE. Grade 3/4 adverse events were similar for pts with and without prior TACE in both arms.


C improved OS and PFS compared with P in pts with previously treated advanced HCC irrespective of whether they had received prior TACE.

Clinical trial identification


Legal entity responsible for the study

The authors.


Exelixis, Inc.

Editorial Acknowledgement


A-L. Cheng: Honoraria, Consulting, Advisory role, Speakers\' bureau: Bayer, Eisai, Ono, Genentech, Novartis, BMS, Merck, MSD. T. Meyer: Consulting, Advisory role: Bayer, BTG, Ipsen; Research funding: Bayer, BTG. J-W. Park: Honararia: Bayer, BMS, Ono; Consulting, Advisory role: BMS, Ono, Bayer, Eisai, Midatech, Roche. H-J. Klümpen: Travel, accommodations and expenses to the ENETS knowledge network, sponsored by Ipsen. J. Knox: Honoraria: Novartis; Consulting or advisory role: Lilly, Merck; Research funding; AstraZeneca. M. Patel: Emplyee, Stock ownership: Exelixis, Genentech/Roche. A.B. El-Khoueiry: Honoraria: BMS, Bayer, Exelixis, EMD Serono, EISAI, Roche, Cytomx, Merck; Consulting or advisory role: BMS, Bayer; Research funding: AstraZeneca, Astex. R.K. Kelley: Consulting or advisory role: Genentech for IDMC (self), Bayer, BMS, AstraZeneca, DebioPharm, Agios; Research funding: Adaptimmune, Agios, AstraZeneca, Bayer, Bristol Myers Squibb, Celgene, Exelixis, Eli Lilly, Medimmune, Merck, Novartis, Regeneron, Sanofi, Taiho, Target Pharma Solutions, Tekmira. G.K. Abou-Alfa: Self Consulting: Agios, Amgen, Antengene, Aptus, Aslan, Astellas, AstraZeneca, Bayer, BMS, Boston Scientifc, Carsgen, Celgene, Casi, Daiichi, Debio, Delcath, Eisai, Exelixis, Halozyme, Inovio, Ipsen, Merck, Onxeo, PCI Biotech, Roche, Sanofi, Servier, Sillajen, Sirtex, Yakult Immediate; Family member consulting: Celgene, CytomX, Gilead, Halozyme, Sanofi, Silenseed Institutional Research Agios, Array, AstraZeneca, Bayer, BMS, Casi, Celgene, Exelixis, Genentech, Incyte, Lilly, Mabvax, Medimmune, Momenta, Novartis, OncoMed Pharmaceuticals, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.